Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer

Lung Cancer

Volumn 60, Issue 2, 2008, Pages 208-214

  Xiong, Jian Ping ^a   Feng, Miao ^a   Qiu, Feng ^a   Xu, Jun ^a   Tao, Qing Song ^a   Zhang, Ling ^a   Xiang, Xiao Jun ^a   Zhong, Lu Xing ^a   Yu, Feng ^a   Ma, Xu Tian ^b   Gong, Wang Yong ^c  

^a NANCHANG UNIVERSITY   (China)

^b Department of Oncology   (China)

^c Department of Oncology   (China)

Author keywords

Cisplatin; Clinical trial; Gemcitabine; Non small cell lung cancer; Prolonged infusion

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; CISPLATIN; CORTICOSTEROID; GEMCITABINE; SEROTONIN 3 ANTAGONIST;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEX DIFFERENCE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 42949093133     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.10.004     Document Type: Article

References (32)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in Non-Small Cell Lung Cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
3. Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alberola V., Monnier A., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12 (1994) 360-367
4. Wozniak A.J., Crowley J.J., Balcerzak S.P., Weiss G.R., Spiridonidis C.H., Baker L.H., et al., A Southwest Oncology Group study. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer. J Clin Oncol 16 (1998) 2459-2465
5. Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E., et al., Results of an Eastern Cooperative Oncology Group trial. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin. J Clin Oncol 18 (2000) 623-631
6. Sandler A.B., Nemunaitis J., Denham C., von Pawel J., Cormier Y., Gatzemeier U., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18 (2000) 122-130
7. Crino L., Scagliotti G.V., Ricci S., De Marinis F., Rinaldi M., Gridelli C., et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17 (1999) 3522-3530
8. Cardenal F., Lopez-Cabrerizo M.P., Anton A., Alberola V., Massuti B., Carrato A., et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17 (1999) 12-18
9. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer Italian Lung Cancer Project. J Clin Oncol 20 (2002) 4285-4291
10. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer Eastern Cooperative Oncology Group. N Engl J Med 346 (2002) 92-98
11. Kelly K., Crowley J., Bunn Jr. P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al., A Southwest Oncology Group trial. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer. J Clin Oncol 19 (2001) 3210-3218
12. Smit E.F., van Meerbeeck J.P., Lianes P., Debruyne C., Legrand C., Schramel F., et al., A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. Three-arm randomized study of two cisplatin based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer. J Clin Oncol 21 (2003) 3909-3917
13. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80
14. Plunkett W., Huang P., Xu Y.Z., Heinemann V., Grunewald R., and Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22 (1995) 3-10
15. Grunewald R., Kantarjian H., Keating M.J., Abbruzzese J.L., Tarassoff P., and Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50 (1990) 6823-6826
16. Grunewald R., Abbruzzese J.L., Tarassoff P., and Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27 (1991) 258-262
17. Ceribelli A., Gridelli C., De Marinis F., Fabi A., GCortesi E., Barduagni M., et al. Prolonged gemcitabine infusion in non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 98 (2003) 337-343
18. Tempero M., Plunkett W., Ruiz Van Haperen V., Hainsworth J., Hochster H., Lenzi R., et al. Randomized phase II comparison of dose intense Gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21 (2003) 3402-3408
19. Xu N., Shen P., Zhang X.C., Yu L.F., Bao H.Y., Shi G.M., et al. Phase II trial of a 2 h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 59 (2007) 1-7
20. Maurel J., Zorrilla M., Puertolas T., Anton A., Herrero A., Artal A., et al. Phase I trial of weekly gemcitabine at 3 h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs 12 (2001) 713-717
21. 2) levels. Invest New Drugs 15 (1997) 115-121
22. Akrivakis K., Schmid P., Flath B., Schweigert M., Sezer O., Mergenthaler H.G., et al. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs 10 (1999) 525-531
23. Schmid P., Akrivakis K., Flath B., Grosse Y., Sezer O., Mergenthaler H.G., et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10 (1999) 625-631
24. Anderson H., Thatcher N., Walling J., and Hansen H. A phase I study of a 24 h infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 74 (1996) 460-462
25. Eckel F., Lersch C., Assmann G., and Schulte-Frohlinde E. Toxicity of a 24 h infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study. Cancer Investig 20 (2002) 180-185
26. Eckel F., Schmelz R., Erdmann J., Mayr M., and Lersch C. Phase II trial of a 24 h infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma 21 (2003) 690-694
27. von Delius S., Lersch C., Schulte-frohlinde E., Mayr M., Schmid R.M., and Eckel F. Phase II trial of weekly 24 h infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 5 (2005) 61
28. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
29. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
30. Xiong J.P., Zhang L., Zhong L., Qiu F., Guo Y.L., Lian H.Y., and Luo H. Phase II trial of prolonged infusion of low-dose gemcitabine in advanced non-small cell lung cancer treatment. Ai Zheng 25 (2006) 995-998
31. Zwitter M., Kovac V., Smrdel U., Kocijancic I., Segedin B., and Vrankar M. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs 16 (2005) 1129-1134
32. Cappuzzo F., Novello S., De Marinis F., Selvaggi G., Scagliotti G.V., Barbieri F., et al. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer 52 (2006) 319-325